Key result
In patients undergoing cardiac resynchronization therapy, the presence of atrial fibrillation did not affect 2-year mortality compared to those without AF.
Why the study?
Does cardiac resynchronization therapy provide similar mortality benefits in patients with atrial fibrillation compared to those without atrial fibrillation?
Cohort (n=175)
No
Does cardiac resynchronization therapy provide similar mortality benefits in patients with atrial fibrillation compared to those without atrial fibrillation?
Cardiac resynchronization therapy appears to offer similar 1- and 2-year survival benefits in heart failure patients regardless of the presence of atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Should not yet change CRT eligibility based on AF; extends observational data but leaves randomized confirmation open.
INTRODUCTION: Atrial fibrillation (AF) is the most common arrhythmia in patients with heart failure (HF) and represents an important comorbidity in these patients. Cardiac resynchronization therapy (CRT) has been shown to be beneficial in patients with HF. Whether patients with AF benefit similarly from CRT as their counterparts in sinus rhythm is controversial. METHODS AND RESULTS: We conducted a cohort analysis of 175 patients (138 men; age range 57-79 years) who underwent CRT implantation during 2004-2008 in our institution. AF was documented in 66 patients (37.7% of patients, 52 men). There were no differences in 1- or 2-year mortality between patients with and without AF (13.6% vs 11.79%, P = 0.7; 25.8% vs 16.9%, P = 0.2, respectively). There were no differences between the groups in the rate of complications after CRT implantation or in the rate of appropriate electrical shocks. In the subgroup of AF patients with cardiac resynchronization therapy defibrillator (CRT-D) (n = 32, 48.5%), the 1-year mortality was 3.1% as compared to 23.5% in AF patients with cardiac resynchronization therapy pacemaker (P = 0.03). This difference was no longer evident after 2 years (25.0% vs 26.5%, P = 0.8, respectively). Ten patients (15.2%) with AF underwent atrioventricular (AV) node ablation. The 2-year mortality of these patients was 10.0% as compared to 28.6% in AF patients who did not undergo AV-node ablation (P = 0.4). CONCLUSIONS: In this study, no difference in mortality appears to exist between patients with or without AF and who undergo CRT implantation. Our findings of the beneficial effects of AV-node ablation and CRT-D in AF patients deserve further investigation.
No takes yet. Share an insight, caveat, or question.
Eisen et al. (2013) conducted a cohort in Heart failure requiring cardiac resynchronization therapy (n=175). Atrial fibrillation vs. No atrial fibrillation was evaluated on 2-year mortality (p=0.2). In patients undergoing cardiac resynchronization therapy, the presence of atrial fibrillation did not affect 2-year mortality compared to those without AF.
Synapse has enriched 10 related papers. Consider them for comparative context: